Scientific Journal Articles that provide Clinical and Pre-clinical data and further insights into Immuron’s technology:
-
IMM-124E clinical study resulting in up to 90% efficacy in prevention of Travelers diarrhoea
Otto W, et al. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. 2011.
-
A detailed investigation of the bioactive components of IMM-124E and development of assays to measure functional activity.
Sears KT, et al. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products. 2017.
-
IMM-529 pre-clinical study indicates protection against C. diff infection and disease recurrence
Hutton ML, et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. 2017.
-
IMM-124E is broadly cross-reactive with shigella species and E. coli strains not present in the IMM-124E vaccine. A pre-clinical study demonstrated 75% efficacy in prevention of diarrhea in non-human primates.
Islam D, et al. Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta). 2023.
-
Microbiome pre-clinical study indicated feeding with IMM-124E increased the abundance of gut-beneficial bacteria
Gore R et al. Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice. 2023.
-
Presentations at the MHSRS conference 2023.
Military Health System Research Symposium 14-17 Aug 2023_Abstract 1
Military Health System Research Symposium 14-17 Aug 2023_Poster 1
Military Health System Research Symposium 14-17 Aug 2023_Immuron Poster
-
Pre-clinical study with colostrum targeting urinary tract infectious E.coli, resulted in prevention of colonization of uropathogenic E.coli in the gut.
Larcombe S, et al. Hyperimmune bovine colostrum reduces gastrointestinal carriage of Uropathogenic E.coli. 2018.
-
IMM-124E pre-clinical study indicated reduction of inflammatory colitis.
Spalinger MR, et al. Administration of the hyper-immune bovine colostrum extract IMM-124E ameliorates experimental murine colitis. 2019.
-
IMM-124E clinical study in patients with Nonalcoholic steatohepatitis (NASH). Results demonstrated oral treatment for 30 days (600mg three times daily) was safe, with no treatment-related adverse events.
Mizrahi M, et al. Alleviation of insulin resistance and liver damage by oral administration of IMM-124E is mediated by increased Tregs and associated with increased serum GLP-I and adiponectin: results of a phase I/II clinical trial in NASH. 2012.
-
Pre-clinical study with colostral antibodies purified from cows immunised with anthrax antigens, demonstrated protection in a series of in vitro cytotoxicity assays.
Paddle BM, et al. The cytotoxic effect of anthrax lethal toxin on human lung cells in vitro and the protective action of bovine antibodies to PA and LF. 2005.
-
Analysis of pre-clinical and clinical sera following COVID-19 infection, indicates treatment with IMM-124E promotes anti-viral immunity by increasing the number of T cells secreting IFNg.
Ishay Y, et al. Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19. 2022.
-
Pre-clinical study with IMM-124E improved symptoms of inflammatory colitis, promoting Treg expression.
Ya’acov AB, et al. The gut microbiome as a target for regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis. 2015.
